Suppr超能文献

SU-E-T-308:一种新型微创巩膜外近距离放射治疗装置的剂量测定

SU-E-T-308: Dosimetry of a New Minimally Invasive Episcleral Brachytherapy Device.

作者信息

Hamilton R, Cetas T, Gordon J, Lutz W, Marsteller L

机构信息

University of Arizona, Tucson, AZ.

Salutaris Medical Devices Inc., Tucson, Arizona.

出版信息

Med Phys. 2012 Jun;39(6Part14):3774. doi: 10.1118/1.4735394.

Abstract

PURPOSE

Describe the dosimetry of an episcleral brachytherapy device.

METHODS

The SMD-I device is designed to treat exudative age-related macular degeneration (AMD) and employs a Sr-90/Y-90 source encapsulated in a stainless steel cylinder. The source is welded to a flexible wire allowing it to travel from a shielded vault in the SMD-I handle to the distal end of a curved cannula to deliver a therapeutic dose of radiation through the sclera to the neovascular target in the subchoroidal space. The SMD-I handle and vault are comprised of Ultem, a lightweight radiation tolerant plastic, which shields the surgeon. Dose calculations were performed using the MCNPX radiation transport code. The absolute dose rate was determined using radiochromic film (GAFChromatic© MD-55) at a point in solid water 2.0mm from the source center perpendicular to the cannula. Dose rates at several depths were measured using Kodak EDR2 film in water equivalent phantoms to compare with the absolute dose rate measurement and MCNPX calculations. The surgeon's hand dose received while manipulating the device with the source in the vault was measured using standard TL (thermoluminescence) finger ring dosimeters, TL ChipstratesTM, and calculated with MCNPX.

RESULTS

The absolute dose rate 2.0mm from the source center is 0.45 Gy/min/mCi. The EDR2 film results agree with the absolute dose measurement and the MCNPX calculations. The dose rate decreases rapidly with depth so that the dose at the target depth (3mm) is approximately 8 times less than at 1mm depth (sclera). The dose distribution is sensitive to the angle between the cannula and the neovascular plane. Both TL methods yield a maximum dose rate of 6 μSv/min mCi to the surgeon's fingers consistent with the MCNPX calculation.

CONCLUSIONS

The SMD-I device permits accurate delivery of a therapeutic radiation dose for the treatment of exudative AMD. Russell J. Hamilton is a founder and currently serves on the Scientific Advisory Board of Salutaris Medical Devices, Inc. Wendell Lutz and Thomas Cetas serve on the Scientific Advisory Board of Salutaris Medical Devices, Inc. All authors have received financial support from Salutaris Medical Devices, Inc.

摘要

目的

描述一种巩膜近距离放射治疗装置的剂量测定。

方法

SMD-I装置旨在治疗渗出性年龄相关性黄斑变性(AMD),采用封装在不锈钢圆柱体内的Sr-90/Y-90源。该源焊接在一根柔性导线上,使其能够从SMD-I手柄中的屏蔽腔移动到弯曲套管的远端,通过巩膜向脉络膜下间隙的新生血管靶点输送治疗剂量的辐射。SMD-I手柄和腔由Ultem制成,这是一种轻质的耐辐射塑料,可保护外科医生。使用MCNPX辐射传输代码进行剂量计算。使用放射变色胶片(GAFChromatic© MD-55)在距源中心垂直于套管2.0mm的固体水中的一点处确定绝对剂量率。在水等效体模中使用柯达EDR2胶片测量几个深度处的剂量率,以与绝对剂量率测量值和MCNPX计算结果进行比较。使用标准热释光(TL)指环剂量计、TL ChipstratesTM测量在源位于腔内时操作该装置时外科医生手部所接受的剂量,并通过MCNPX进行计算。

结果

距源中心2.0mm处的绝对剂量率为0.45 Gy/min/mCi。EDR2胶片结果与绝对剂量测量值和MCNPX计算结果一致。剂量率随深度迅速降低,因此靶点深度(3mm)处的剂量约比1mm深度(巩膜)处低8倍。剂量分布对套管与新生血管平面之间的角度敏感。两种TL方法对外科医生手指产生的最大剂量率均为6 μSv/min mCi,与MCNPX计算结果一致。

结论

SMD-I装置允许准确输送治疗性辐射剂量以治疗渗出性AMD。拉塞尔·J·汉密尔顿是Salutaris医疗器械公司的创始人,目前在该公司科学顾问委员会任职。温德尔·卢茨和托马斯·塞塔斯在Salutaris医疗器械公司科学顾问委员会任职。所有作者均获得了Salutaris医疗器械公司的资金支持。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验